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Abstract 
 
The active vitamin D metabolite 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3, Calcitriol) 
is a major regulator of gene expression in higher organisms. Protein abundance is an 
endpoint of gene expression that results from the balance between induction and 
degradation and is essential for adequate cell function. Proteins are degraded by 
proteases whose activity is in turn controlled by a number of endogenous protease 
inhibitors. 1,25(OH)2D3 regulates several proteases and protease inhibitors in different 
cell types, putatively contributing to its regulatory effects of cell physiology. We have 
recently shown that 1,25(OH)2D3 strongly induces the expression of cystatin D, an 
inhibitor of several cysteine proteases of the cathepsin family. Cystatin D induction may 
contribute to the antitumor effect of 1,25(OH)2D3 against colon cancer by mechanisms 
that are both dependent and independent of cathepsin inhibition. Transcriptomic studies 
suggest that 1,25(OH)2D3 also modulates the function of the ubiquitin-proteasome 
system. Thus, proteases and protease inhibitors are candidates to mediate to a certain 
extent the complex action of 1,25(OH)2D3 in cancer cells. 
 
 
Running title: Vitamin D regulates cellular protein degradation. 
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Protein degradation: proteases and protease inhibitors 
In healthy cells and organisms the balance between protein production and degradation 
is of crucial importance. Proteins are degraded by proteolytic enzymes (proteases). They 
are classified in five major classes based on the specific chemical groups responsible for 
the catalysis (serine-, cysteine-, aspartic-, threonine- and metallo-proteases).
1
 Most 
proteases are relatively nonspecific for substrates but some of them show specificity 
toward a single peptide bond of a particular protein. The complete set of proteases 
produced by human cells consists of at least 569 proteases and homologues distributed 
into these five classes.
2
 
The action of proteases is tightly controlled by a powerful regulatory system. A 
crucial role in the regulation of protease activity is exerted by endogenous protease 
inhibitors. They protect cells and tissues against the proteolytic activity of proteases that 
are often secreted by or released from normal dying cells or in pathologic situations 
such as tumor progression.
3
 Endogenous inhibitors are always proteins but their number 
is much lower than that of proteases. One of the systems used to classify these inhibitors 
is based on the catalytic class of proteases they target.  
Another critical component of the protein degradation machinery is the 
ubiquitin-proteasome system (UPS), which operates both in the nucleus and in the 
cytosol.
4
 UPS consists of a large number of proteins that are dedicated to the 
identification, targeting and destruction of unneeded or damaged proteins by 
proteolysis. Proteins are tagged for degradation by a small protein (8.5 kDa) called 
ubiquitin. This is a multistep process that involves at least three classes of enzymes 
generally known as ubiquitinating enzymes (UBs): ubiquitin-activating enzymes (E1), 
ubiquitin-conjugating enzymes (E2) and ubiquitin protein ligases (E3). In addition, 
deubiquitinating enzymes (DUBs) also play a crucial role regulating this process.
5
 The 
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proteasome contains a barrel-shaped proteolytic core complex (the proteasome 20S) 
capped at one or both ends by 19S regulatory complexes, which recognize ubiquitinated 
proteins. This multicatalytic system includes three different types of proteases with 
complementary activities: chymotrypsin-like, trypsin-like, and caspase-like activities.
6
 
Proteases, especially those that degrade extracellular matrix (the ECM), play an 
important role in tumor development providing access for tumor cells to the vascular 
and lymphatic systems, thus favoring angiogenesis and invasion. Moreover, certain 
proteases also promote tumor cell proliferation and resistance to apoptosis showing that 
proteolytic enzymes can contribute to all stages of tumor progression.
7-9
 Accordingly, 
proteases have been studied in multiple cancer types, with special attention to the matrix 
metalloprotease (MMP) family but also, more recently, to the cysteine and serine 
protease families. Due to the crucial role of proteases in tumor development, the 
identification and study of their inhibitors and their role in tumor progression are of 
pressing interest. Remarkably, however, recent studies have provided evidence of intra- 
and extra-cellular proteases with antitumor properties.
2, 10, 11
 These results support an 
emerging and paradoxical role for some proteases in tumor suppression. 
 
Vitamin D has antitumor effects 
Vitamin D is a fat-soluble secosteroid prohormone obtained from diet, dietary 
supplements and, mainly, from the conversion of 7-dehydrocholesterol to vitamin D3 in 
the skin by the action of solar UV-B radiation (280-320 nm). The active form of vitamin 
D3, 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3, Calcitriol), is obtained after 25-
hydroxylation of vitamin D3 in the liver and subsequent 1α-hydroxylation in the kidney 
and in certain vitamin D target tissues. 1,25(OH)2D3 has pleiotropic effects in the 
organism: in addition to regulating calcium and phosphate metabolism and bone 
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biology, it has antiproliferative, anti-invasive, pro-apoptotic and prodifferentiation 
activity. These novel actions suggest, together with epidemiological data and the results 
of experimental studies, a protective role of 1,25(OH)2D3 against several neoplasias 
(reviewed in ref. 
12
). To avoid the toxic hypercalcemic effect associated with the high-
dose 1,25(OH)2D3 treatments required for in vivo activity, many derivatives generically 
termed deltanoids have been synthesized.
13, 14
 
1,25(OH)2D3 and its analogs act by interacting with their high affinity receptor 
(vitamin D receptor, VDR), through a complex network of genomic and non-genomic 
mechanisms.
15-17
 To exert its genomic effects, VDR forms heterodimers with another 
nuclear receptor (retinoid X receptor, RXR), which interacts with specific DNA 
sequences known as vitamin D response elements (VDREs) in target genes (reviewed in 
ref. 
18
). Global transcriptomic studies have identified a large number of candidate 
1,25(OH)2D3 target genes in several types of human tumoral cells.
19-25
 They include 
genes coding for proteins with a wide variety of functions that are responsible for the 
antitumor action of 1,25(OH)2D3. Remarkably, some genes encode both proteases and 
protease inhibitors. 
 
Vitamin D regulates cystein proteases and cystatins 
Recently, we have demonstrated in human colon cancer cells that 1,25(OH)2D3 induces 
the expression of cystatin D, an inhibitor of several cysteine proteases of the cathepsin 
family, which had not been previously linked  to cancer.
26
  Cystatin D has a narrow 
inhibitory profile. Unlike other members of the cystatin family, it inhibits only cathepsin 
S, H, and L, but not cathepsin B, the most widely characterized cathepsin. In addition, 
cystatin D expression had only been found in parotid and submandibular glands and 
saliva.
27, 28
 Cystatin D was identified as a candidate 1,25(OH)2D3 target gene in a 
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transcriptomic analysis performed in human SW480-ADH colon cancer cells.
22
 
1,25(OH)2D3 increases cystatin D RNA and protein expression in these cells due to a 
direct transcriptional activation that required functional VDR.
26
 Transactivation assays 
showed that full activation is mediated by a cluster of VDR binding sites located close 
to the transcription start site at the cystatin D promoter. This is consistent with the 
proposal that isolated, simple VDREs may be not functional in vivo but that, on the 
contrary, VDR binding site clusters or modules contribute to chromatin decondensation 
which makes it easier for the transcription machinery to accede to the promoter.
18
 
Importantly, ectopic expression of cystatin D in SW480-ADH cells inhibits 
proliferation, mimicking the effect of 1,25(OH)2D3. The expression of certain genes was 
also similarly altered by exogenous cystatin D and by 1,25(OH)2D3. Thus, classical 
target genes of 1,25(OH)2D3 such as CDH1 encoding the adhesion protein E-cadherin or 
the c-MYC oncogene were induced or repressed, respectively, in cystatin D-expressing 
cells. To corroborate the hypothesis that cystatin D was an important mediator of 
1,25(OH)2D3 actions, we knocked-down cystatin D by stable shRNA expression. We 
found that the antitumor effects of 1,25(OH)2D3, such as the acquisition of a highly 
adhesive epithelial phenotype and the inhibition of proliferation, were partially blocked 
in these cells. In contrast to the effect of cystatin D overexpression, cystatin D knocked-
down cells showed decreased expression of E-cadherin protein and increased expression 
of c-MYC.
26
 Together, our data indicate that cystatin D has an unexpected crucial role 
in 1,25(OH)2D3 antitumor activity in human colon cancer cells (Fig.1). 
How this protease inhibitor exerts its action is unclear. Based on our results 
obtained using mutant cystatin D proteins with reduced antiproteolytic activity, it seems 
that not all the antitumor effects of cystatin D are mediated by the inhibition of 
cathepsins. Thus, the reduction of cell proliferation and c-MYC downregulation are 
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independent of cathepsin inhibition (Fig. 1).
26
 These results open the door to further 
studies to identify the mechanism by which this protease inhibitor partly exerts its 
antitumor effects and contributes to the action of 1,25(OH)2D3. The finding that cystatin 
D was also regulated by the 1,25(OH)2D3 analog EB1089 in xenografted mice and the 
significant correlation found between cystatin D expression and VDR protein levels in 
human colon cancer biopsies sustain a role for 1,25(OH)2D3 in the regulation of cystatin 
D in vivo.
26
 
Cystatin D is not the only cystatin regulated by 1,25(OH)2D3. Previously, 
cystatin E/M had been identified as a target of the 1,25(OH)2D3 analog EB1089 in 
squamous carcinoma cells. The upregulation of cystatin E/M by the hormone was 
confirmed by Northern blot and immunofluorescence analyses.
20
 Interestingly, cystatin 
E/M is downregulated in cancer, and several authors relate the loss of its expression 
with breast cancer progression and propose it as a tumor suppressor.
29-31
 However, no 
functional studies relating cystatin E/M and 1,25(OH)2D3 in squamous cell carcinoma 
have been reported. Similarly, cystatin A is regulated by 1,25(OH)2D3 in normal 
keratinocytes. This protease inhibitor is considered a differentiation marker for this 
particular cell type. 1,25(OH)2D3 increases human cystatin A expression by inhibiting 
the Raf-1/MEK1/ERK signaling pathway via a non-genomic response.
32
 
The view emerging from all these studies is that cystatins are used by 
1,25(OH)2D3 as mediators of its genomic and non-genomic effects. At least part of the 
contribution of cystatins to 1,25(OH)2D3 action seems to be independent of its capacity 
to inhibit cathepsin activity. 
Although the regulation of cystatins by 1,25(OH)2D3 is a relatively recent 
finding, the induction of cathepsin B by 1,25(OH)2D3 in breast cancer cells was first 
reported in 1996.
33
 Cathepsin B is a ubiquitously expressed cysteine protease that has 
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been described as a general marker of apoptosis and plays an important role in the cell 
death induced by tumor necrosis factor (TNF) . Cathepsin B is released from 
lysosomes during TNFα-induced apoptosis and promotes the release of mitochondrial 
cytochrome c.
34-36
 In breast cancer cells, 1,25(OH)2D3-induced apoptosis requires the 
dissipation of mitochondrial membrane potential leading to the release of cytochrome c, 
the generation of oxidative stress and the redistribution of BAX from the cytosol to 
mitochondria.
37
 Therefore, cathepsin B induction by 1,25(OH)2D3 could be attributed to 
the pro-apoptotic activity of the hormone. In addition, the induction of cathepsin B by 
1,25(OH)2D3 in MCF-7 breast cancer cells enhances TNF -induced apoptosis.
38
 
However, the induction of cathepsin B by 1,25(OH)2D3 does not seem to play a central 
role in the apoptotic pathway but may rather be a downstream event in the induction of 
cell death.
37, 38
 
Another member of the cathepsin family, cathepsin L, has been reported to be a 
target of 1,25(OH)2D3. A transcriptomic analysis, later confirmed by qRT-PCR, showed 
that the expression of cathepsin L is inhibited by 1,25(OH)2D3 in MDA-MB-231 breast 
cancer cells.
23
 This protease has been related with the promotion of malignancy in 
multiple cancer types and its inhibition by 1,25(OH)2D3 could be part of the antitumor 
action of 1,25(OH)2D3 in breast cancer. 
 
Vitamin D modulates the activity of matrix metalloproteases and 
serine proteases 
Matrix metalloproteases (MMPs) are a family of zinc-dependent proteases capable of 
degrading components of the extracellular matrix and basement membrane. MMPs are 
regulated by the action of specific inhibitors: the tissue inhibitors of metalloproteases 
(TIMPs). Both MMPs and TIMPs are frequently disrupted in cancer, which promotes 
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the migration and invasion of cancer cells. A number of studies have shown the 
regulation of MMPs and/or TIMPs by 1,25(OH)2D3. Treatment with 1,25(OH)2D3 of 
breast and prostate cancer cells decreases expression of MMP-9 and increases TIMP-1 
levels.
39, 40
 The modulation of the MMP/TIMP balance may be a mechanism by which 
1,25(OH)2D3 inhibits invasion. In addition, EB1089 inhibits MMP-13 and, surprisingly, 
induces MMP-1 and MMP-3 RNA expression in squamous cell carcinoma lines.
20
 The 
fact that each MMP has specific, and still not completely understood, function may 
eventually explain the differences in their regulation by 1,25(OH)2D3. In fact, MMP-3 is 
considered a dual protease in terms of cancer-modulating properties.
2
 
Researchers have also analyzed the effect of 1,25(OH)2D3 on the expression of 
urokinase and tissue plasminogen activators (uPA and tPA, respectively) as well as their 
inhibitors (PAIs). The serine proteases uPA and tPA convert the proteolytically inactive 
plasminogen into plasmin, a wide-spectrum protease capable of degrading ECM and 
basement membrane proteins and activating pro-MMPs. 1,25(OH)2D3 decreases the 
secretion of uPA and tPA and increases that of PAI-1 in breast cancer cells, leading to a 
reduction in total PA activity.
39
 This 1,25(OH)2D3-mediated regulation of the 
plasminogen activator system was observed in breast- but not in prostate-cancer cells.
39, 
40
 Quantitative RT-PCR studies recently performed in our laboratory revealed that 
1,25(OH)2D3 causes a 2.3-fold increase in the expression of PAI-1 in SW480-ADH 
human colon cancer cells. Additional work is nedeed to elucidate the possible 
contribution of this inhibitor to the antitumor effects of 1,25(OH)2D3 in colon cancer. 
1,25(OH)2D3 also regulates other members of the serine protease family. 
Transcriptomic studies using oligonucleotide microarrays performed by us and others 
have identified protease M, also known as neurosin/zyme/kallikrein-6 (KLK-6) as a 
target gene of 1,25(OH)2D3 in colon cancer and squamous carcinoma cell lines.
20, 22
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Protease M is a member of the kallikrein (KLK) family, which includes secreted serine 
proteases with a wide-range of expression that are commonly regulated by steroid 
hormones in several cancer cell lines.
41
 The induction of protease M after 1,25(OH)2D3 
treatment was confirmed by Northern blotting and immunofluorescence.
20, 22
 We also 
found that, similarly to protease M, normal epithelial cell-specific 1 (NES1), another 
member of the kallikrein family (KLK-10), was induced by 1,25(OH)2D3 in SW480-
ADH human colon cancer cells. This result was confirmed by Northern blot.
22
 Data 
from our laboratory also revealed that KLK-7 RNA expression is induced 9.5-fold by 
1,25(OH)2D3 in these cells. The putative role of these serine proteases in 1,25(OH)2D3 
action is unknown since no functional studies have been reported. Paradoxically, recent 
studies have proposed protease M as a marker of poor prognosis in ovarian and colon 
cancer, while NES1 has been described as a marker of either favorable or unfavorable 
prognosis depending on the cancer type (ref. 
42
 and refs. therein). Other hitherto 
unknown functions of these proteases could contribute to the antitumor action of 
1,25(OH)2D3, as a dual role in tumor progression has been proposed for other 
proteases.
2
 
 
Vitamin D and the ubiquitin-proteasome system 
The ubiquitin-proteasome system (UPS) has been implicated in cancer and 
chemotherapy action.
4, 43
 The rationale behind this is the control by the UPS of 
transcription factors and components of the apoptotic machinery that play important 
roles in the control of cell phenotype and survival. The clinical use of the proteasome 
inhibitor Bortezomib (Velcade®) against multiple myeloma is a proof-of-concept. 
Transcriptomic analyses using human SW480-ADH colon cancer cells performed in our 
laboratory have revealed numerous UPS genes as candidate targets of 1,25(OH)2D3 
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(Table I). These genes include a group encoding ubiquitinating (UBs) and 
deubiquitinating (DUBs) enzymes and another group corresponding to components of 
the proteasome particle. The effect observed is an almost general repression of these 
genes at 48 h of 1,25(OH)2D3 treatment. This could be related to the antitumoral action 
of the hormone, as cancer cells have higher level of proteasome activity than their 
normal counterparts.
4
 
Ubiquitin-mediated events are critical for cell function and proliferation, and the 
association of DUBs with cancer is increasingly recognized.
44
 The list of transcription 
factors regulated by the UPS includes both oncogenes and tumor suppressor genes.
4 
Moreover, the stability and function of nuclear factor kappa B are tightly regulated by 
the proteasome. The extremely wide function of the UPS and our limited knowledge of 
the control of the stability of many of the proteins that are critical in cancer make very 
difficult to extrapolate or even speculate about the role and consequences of the 
regulation by 1,25(OH)2D3 of the large series of UPS genes. The first step undoubtedly 
must be to validate their regulation and then to analyze its effects at the cell level, a task 
that is hampered by the complexity of the UPS. 
 
Conclusions 
1,25(OH)2D3 has a wide range of antitumor activity that has only partially been 
characterized. Numerous studies have shown that it is a major transcriptional regulator 
of gene expression. However, the large number of genes regulated by 1,25(OH)2D3 that 
are related with the protein degradation machinery (proteases, protease inhibitors and 
components of the UPS) suggests a new role of 1,25(OH)2D3 as a post-translational 
regulator. Thus, the antitumor activity of 1,25(OH)2D3 may be exerted by a dual 
transcriptional and post-translational regulation of its target genes. Clearly, validation of 
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candidate 1,25(OH)2D3 target genes of UPS as well as functional studies with other 
proteases and protease inhibitors known to be regulated by 1,25(OH)2D3 are necessary 
to corroborate this view. 
 14 
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Table I. 
Candidate 1,25(OH)2D3 target genes of the ubiquitin-proteasome system in SW480-
ADH human colon cancer cells. RNA levels (fold-change) at 4 or 48 h treatment with 
100 nM 1,25(OH)2D3 as compared to vehicle-treated cells obtained using 
oligonucleotide microarrays. 
GENE FOLD CHANGE 
Symbol Name 
1,25(OH)2D3 (h) 
4              48 
   Ubiquitin-conjugating enzymes (E2)   
CDC34 Ubiquitin-conjugating enzyme CDC34 2.46  
UBE2M Ubiquitin-conjugating enzyme E2M 2.30 -3.03 
UBE2D3 Ubiquitin-conjugating enzyme E2D 3  2.00 
UBE2E3 Ubiquitin-conjugating enzyme E2E 3  -2.00 
UBE2L3 Ubiquitin-conjugating enzyme E2L 3  -2.00 
UBE2N Ubiquitin-conjugating enzyme E2N  -2.00 
UBE2C Ubiquitin-conjugating enzyme E2C  -2.14 
    Ubiquitin protein ligases (E3)   
UBE3A Ubiquitin protein ligase E3A -2.00  
WWP1 WW domain containing E3 ubiquitin protein ligase 1 -2.30  
    Deubiquitinating enzymes (DUB)   
USP5 Ubiquitin specific peptidase 5 2.46  
USP9X Ubiquitin specific peptidase 9, X-linked  2.30 
USP13 Ubiquitin specific peptidase 13  -2.14 
   Other ubiquitin-related genes   
UBE4B Ubiquitination factor E4B -2.46 -2.64 
UBC Ubiquitin C  2.14 
    Proteasome 20S   
PSMB4 Proteasome subunit, beta type, 4 2.46 -2.00 
PSMB10 Proteasome subunit, beta type, 10 2.46 -2.14 
PSMB3 Proteasome subunit, beta type, 3  -2.46 
PSMB2 Proteasome subunit, beta type, 2  -3.25 
    
Proteasome 19S   
PSMD13 Proteasome 26S subunit, non-ATPase, 13 2.83 -2.83 
PSMD3 Proteasome 26S subunit, non-ATPase, 3 2.30 -2.14 
PSMD7 Proteasome 26S subunit, non-ATPase, 7  2.00 
PSMD8 Proteasome 26S subunit, non-ATPase, 8  -2.30 
    Other proteasome-related genes   
PSMF1 Proteasome inhibitor subunit 1  2.64 
PSME2 Proteasome activator subunit 2  -2.30 
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Figure legend 
Figure 1. 
The protease inhibitor cystatin D is induced by 1,25(OH)2D3 and mediates, at least 
partially, its antitumor activity in colon cancer by cathepsin inhibition-dependent and -
independent mechanisms (see ref. 
26
 for a detailed description). 
 
